Last updated 2026-08-22
Total raised
—
Stage
—
Founded
2024
Headcount
—
HQ
Yokne'am Illit, Israel
Sector
Biomed
About
EndoSpot is developing a novel, local, targeted, sustained-release system for Endometriosis, a chronic inflammatory disease affecting 10% of reproductive-age women globally. The system delivers an effective treatment directly to peritoneal lesions, minimizing systemic exposure and avoiding severe side effects associated with hormonal interventions. Their lead product is in preclinical development, with future applications including other localized therapies for endometriosis and adenomyosis.
Q&A
- What is EndoSpot Ltd. developing?
- EndoSpot Ltd. is developing a novel, local, targeted, sustained-release system for Endometriosis, a chronic inflammatory disease affecting women.
- When was EndoSpot Ltd. founded?
- EndoSpot Ltd. was founded in 2024.
- Where is EndoSpot Ltd. headquartered?
- EndoSpot Ltd. is headquartered in Yokne'am Illit, Israel.
- Who are the co-founders of EndoSpot Ltd.?
- The co-founders of EndoSpot Ltd. are Ronya Rubinstein (CEO), Jaron Breitman (CIO), and Salit Tzaban (CTO).
- What is the primary sector of EndoSpot Ltd.?
- EndoSpot Ltd.'s primary sector is Biomed.
- What stage of development is EndoSpot Ltd.'s lead product in?
- EndoSpot Ltd.'s lead product is currently in preclinical development.
- What are the potential future applications of EndoSpot Ltd.'s technology?
- Future applications of EndoSpot Ltd.'s technology include other localized therapies for endometriosis and adenomyosis.
Team · 3
Ronya Rubinstein
Founder · CEO & Co-Founder
Jaron Breitman
Founder · CIO & Co-Founder
Sectors & technology
Primary sector
Biomed
Technologies
Target customers
Business model
B2C
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
Identifiers & details
| Legal name | ENDOSPOT LTD |
|---|---|
| Founded | 2024 |